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Background: Accumulating evidence suggests that angiotensin-converting enzyme activity may in part mediate neoinimal hyperplasia after 
stenting and progression of atherosclerotic disease. We hypothesize that use of valsartan might suppress intimal hyperplasia after coronary stenting 
and might influence regression of native atheromatous plaque.
Methods: The Val-SUPPRESS trial is a prospective, randomized, multi-center, open-labeled trial. We randomly assigned a total of 220 patients with 
de novo coronary disease receiving paclitaxel-eluting or zotarolimus-eluting stents to receive valsartan 160 mg daily with open treatment or not. 
The primary end point was an in-stent late loss of the stented segments at 8-month angiographic follow-up. Secondary end points included serial 
changes of percent atheroma volume of non-stented, intermediate lesions (i.e., most diseased 10-mm segment) by intravascular ultrasound, and 
clinical outcomes (death, myocardial infarction, and repeat revascularization). 
Results: A total of 220 patients were randomized 1:1 to received valsartan treatment (n=108) or not (n=112). Eight-month angiographic follow-
up was performed in 86% of overall patients. The primary end-point of in-stent late loss was similar in patients receiving valsartan and in those not 
receiving valsartan (0.52±0.40 and 0.54±0.50, P=0.64). The rate of angiographic restenosis and the combined and individual clinical endpoints 
were also similar between 2 groups. However, the mean (SD) change in atheroma area in the most diseased 10-mm subsegment significantly differ 
(-1.24±2.22 mm2 in the valsartan group and 0.17±1.50 mm2 in the no-valsartan group, P=0.01). Change in regression of atheroma volume was 
also significantly higher in the valsartan group than in the no-valsartan group (-7.86±11.00 mm3 and -2.10±9.61 mm3, P=0.05).
Conclusions: Valsartan treatment did not significantly reduce neointimal hyperplasia after drug-eluting stents implantation. However, valsartan 
treatment resulted in significant regression of atherosclerosis in native coronary disease. Further studies are needed to determine the effect of the 
observed changes on clinical outcome.
